[HTML][HTML] Protein interaction networks in neurodegenerative diseases: From physiological function to aggregation

G Calabrese, C Molzahn, T Mayor - Journal of Biological Chemistry, 2022 - ASBMB
The accumulation of protein inclusions is linked to many neurodegenerative diseases that
typically develop in older individuals, due to a combination of genetic and environmental …

[HTML][HTML] The metalloproteinase ADAM10: A useful therapeutic target?

S Wetzel, L Seipold, P Saftig - … et Biophysica Acta (BBA)-Molecular Cell …, 2017 - Elsevier
Proteolytic cleavage represents a unique and irreversible posttranslational event regulating
the function and half-life of many intracellular and extracellular proteins. The …

Cholinergic differentiation of human neuroblastoma SH-SY5Y cell line and its potential use as an in vitro model for Alzheimer's disease studies

LM de Medeiros, MA De Bastiani, EP Rico… - Molecular …, 2019 - Springer
Cholinergic transmission is critical to high-order brain functions such as memory, learning,
and attention. Alzheimer's disease (AD) is characterized by cognitive decline associated …

[HTML][HTML] The amyloid cascade hypothesis 2.0 for Alzheimer's disease and aging-associated cognitive decline: from molecular basis to effective therapy

V Volloch, S Rits-Volloch - International Journal of Molecular Sciences, 2023 - mdpi.com
With the long-standing amyloid cascade hypothesis (ACH) largely discredited, there is an
acute need for a new all-encompassing interpretation of Alzheimer's disease (AD). Whereas …

[HTML][HTML] Alpha-secretase ADAM10 regulation: insights into Alzheimer's disease treatment

R Peron, IP Vatanabe, PR Manzine, A Camins… - Pharmaceuticals, 2018 - mdpi.com
ADAM (a disintegrin and metalloproteinase) is a family of widely expressed, transmembrane
and secreted proteins of approximately 750 amino acids in length with functions in cell …

Sphingolipids in Alzheimer's disease, how can we target them?

SM Crivelli, C Giovagnoni, L Visseren… - Advanced drug delivery …, 2020 - Elsevier
Altered levels of sphingolipids and their metabolites in the brain, and the related
downstream effects on neuronal homeostasis and the immune system, provide a framework …

[HTML][HTML] Redox-active metal ions and amyloid-degrading enzymes in Alzheimer's disease

N Kim, HJ Lee - International Journal of Molecular Sciences, 2021 - mdpi.com
Redox-active metal ions, Cu (I/II) and Fe (II/III), are essential biological molecules for the
normal functioning of the brain, including oxidative metabolism, synaptic plasticity …

[HTML][HTML] ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker

PR Manzine, M Ettcheto, A Cano, O Busquets… - Biomedicine & …, 2019 - Elsevier
Alzheimer's disease (AD) represents a global burden in the economics of healthcare
systems. Amyloid-β (Aβ) peptides are formed by amyloid-β precursor protein (AβPP) …

A new generation of AD biomarkers: 2019 to 2021

J Hawksworth, E Fernandez, K Gevaert - Ageing research reviews, 2022 - Elsevier
Alzheimer's disease (AD) is the most common form of dementia and cases are rising
worldwide. The effort to fight this disease is hampered by a lack of disease-modifying …

[HTML][HTML] Therapeutic potential of ADAM10 modulation in Alzheimer's disease: a review of the current evidence

MR Khezri, M Mohebalizadeh… - Cell Communication and …, 2023 - Springer
Abstract Alzheimer's disease (AD), the most common neurodegenerative disease
worldwide, is caused by loss of neurons and synapses in central nervous system. Several …